Department of Ophthalmology, Ondokuzmayıs University Hospital, Samsun, Turkey.
Clin Exp Optom. 2023 Nov;106(8):852-858. doi: 10.1080/08164622.2022.2133596. Epub 2022 Nov 14.
Proliferative vitreoretinopathy (PVR) is still the leading cause of surgical failure after rhegmatogenous retinal detachment (RRD) repair. The factors that can predict the development of PVR remain to be elucidated.
This study evaluates the predictive values of the systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratio in patients with primary RRD with and without PVR.
A total of 150 patients with RRD and 51 age- and sex-matched healthy participants were included in the study. Patients who developed PVR within three months after surgery were enrolled as PVR cases (n = 75, Group 1), and those who did not develop PVR were enrolled in RRD without the PVR group (n = 75, Group 2). Ocular examination findings and medical records of all participants were analysed retrospectively. Peripheral blood samples were collected, and systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, and platelet-to-lymphocyte ratios were calculated. The systemic immune-inflammation index calculation formula is: (Neutrophil/lymphocyte) × Platelet.
The median neutrophil-to-lymphocyte ratio and systemic immune-inflammation index levels were significantly higher in Group 1 patients compared to Group 2 and the control groups (p = 0.01, for both). However, the groups were similar regarding median platelet-to-lymphocyte ratio (p = 0.917). The optimal cut-off values of neutrophil-to-lymphocyte ratio and systemic immune-inflammation index were calculated as 1.72 (with 72% sensitivity and 48% specificity) and 407.9 (with 72% sensitivity and 49.3% specificity), respectively, for predicting PVR development in patients with RRD.
Neutrophil-to-lymphocyte ratio and systemic immune-inflammation index may be useful biomarkers for predicting the risk of PVR development in RRD patients.
增生性玻璃体视网膜病变(PVR)仍然是孔源性视网膜脱离(RRD)修复后手术失败的主要原因。能够预测 PVR 发展的因素仍有待阐明。
本研究评估了全身免疫炎症指数、中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值在原发性 RRD 伴或不伴 PVR 患者中的预测价值。
共纳入 150 例 RRD 患者和 51 名年龄和性别匹配的健康对照者。术后 3 个月内发生 PVR 的患者被纳入 PVR 组(n=75,第 1 组),未发生 PVR 的患者被纳入 RRD 无 PVR 组(n=75,第 2 组)。回顾性分析所有参与者的眼部检查结果和病历。采集外周血样,计算全身免疫炎症指数、中性粒细胞与淋巴细胞比值和血小板与淋巴细胞比值。全身免疫炎症指数的计算公式为:(中性粒细胞/淋巴细胞)×血小板。
与第 2 组和对照组相比,第 1 组患者的中性粒细胞与淋巴细胞比值和全身免疫炎症指数中位数明显更高(均 p=0.01)。然而,各组血小板与淋巴细胞比值中位数相似(p=0.917)。中性粒细胞与淋巴细胞比值和全身免疫炎症指数预测 RRD 患者发生 PVR 的最佳截断值分别计算为 1.72(灵敏度为 72%,特异性为 48%)和 407.9(灵敏度为 72%,特异性为 49.3%)。
中性粒细胞与淋巴细胞比值和全身免疫炎症指数可能是预测 RRD 患者 PVR 发展风险的有用生物标志物。